alloCART-19 cell therapy / Fudan University - LARVOL DELTA

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Children's Hospital of Fudan University | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Oct 2023 ➔ Oct 2024

CAR T-Cell Therapy • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • CD4

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Children's Hospital of Fudan University | Trial completion date: Jul 2022 ➔ Jul 2024 | Trial primary completion date: Oct 2021 ➔ Oct 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=6; Recruiting; Sponsor: Children's Hospital of Fudan University; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukaemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=6; Recruiting; Sponsor: Children's Hospital of Fudan University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open